newsfilter
← Latest News
GlobeNewswire·

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

  • Tarsus Pharmaceuticals, Inc. will host a live webcast on Wednesday, May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
  • The webcast will cover first quarter 2026 financial results & provide a corporate update.
  • A recorded version of the call will be available shortly after the event & archived for approximately 90 days.
  • XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for treating Demodex blepharitis.
  • Tarsus is developing TP-04, an ophthalmic gel for ocular rosacea, & TP-05, an oral tablet for Lyme disease prevention, both in Phase 2.